Axa S.A. Raises Stock Position in OraSure Technologies, Inc. (NASDAQ:OSUR)

Axa S.A. grew its holdings in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 2.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 161,614 shares of the medical instruments supplier’s stock after buying an additional 3,997 shares during the quarter. Axa S.A. owned 0.22% of OraSure Technologies worth $688,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. lifted its stake in shares of OraSure Technologies by 1,502.3% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 89,714 shares of the medical instruments supplier’s stock valued at $382,000 after purchasing an additional 84,115 shares during the last quarter. Squarepoint Ops LLC lifted its position in OraSure Technologies by 1,348.5% in the second quarter. Squarepoint Ops LLC now owns 249,641 shares of the medical instruments supplier’s stock worth $1,063,000 after buying an additional 232,407 shares during the last quarter. Cubist Systematic Strategies LLC boosted its stake in OraSure Technologies by 573.6% during the second quarter. Cubist Systematic Strategies LLC now owns 206,612 shares of the medical instruments supplier’s stock worth $880,000 after buying an additional 175,937 shares during the period. Marshall Wace LLP bought a new position in OraSure Technologies during the second quarter valued at $203,000. Finally, Sei Investments Co. raised its stake in shares of OraSure Technologies by 76.9% in the second quarter. Sei Investments Co. now owns 302,043 shares of the medical instruments supplier’s stock valued at $1,287,000 after acquiring an additional 131,295 shares during the period. Institutional investors own 93.50% of the company’s stock.

OraSure Technologies Stock Down 2.3 %

Shares of NASDAQ OSUR opened at $4.17 on Wednesday. OraSure Technologies, Inc. has a twelve month low of $3.91 and a twelve month high of $8.45. The firm has a market cap of $308.41 million, a PE ratio of 13.90 and a beta of 0.05. The business has a fifty day simple moving average of $4.32 and a two-hundred day simple moving average of $4.81.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $0.03 earnings per share for the quarter. OraSure Technologies had a return on equity of 9.15% and a net margin of 9.88%. The firm had revenue of $54.34 million during the quarter, compared to the consensus estimate of $53.35 million. On average, research analysts expect that OraSure Technologies, Inc. will post -0.11 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on OSUR. Evercore ISI lifted their price target on shares of OraSure Technologies from $4.50 to $5.00 and gave the stock an “in-line” rating in a research note on Wednesday, August 7th. StockNews.com cut OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Saturday, August 17th. Three analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat, OraSure Technologies currently has an average rating of “Hold” and an average target price of $6.67.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.